The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Todos Medical said on Tuesday that it has signed a letter of intent with Acumen Diagnostics of Singapore under which its Provista Diagnostics subsidiary will offer Acumen's AcuSept sepsis test in the US.

QuidelOrtho Corporation celebrates Women’s History Month by announcing that the QuidelOrtho Women’s Leadership Network (QWLN) has been formed, creating an enhanced network with 14 global leaders supporting 16 chapters around the world.

On March 28, Sinopharm (Shanghai) Medical Device Supply Chain Co., Ltd. and Calibra signed a strategic cooperation agreement in Hangzhou, China.

DiaSorin said on Monday that its full-year 2022 revenues grew 10 percent year over year on "solid performance" across all its businesses.

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the AmoyDx Pan Lung Cancer PCR Panel as a companion diagnostic to direct the use of Eli Lilly's Retevmo (selpercatinib) in RET fusion-positive non-small cell lung cancer.

On March 27, 2023, MGI and Fujian Berry Oncology Co., Ltd. signed the strategic cooperation agreement.

According to Kalorama Information, the U.S. IVD market reached $53 billion in 2022, or approximately 40% to 45% of the global market. Projected growth is 2.4% annually on average through 2027.

Quest Diagnostics has introduced two Post-COVID-19 panels for consumers that offer information about lingering health issues associated with previous COVID-19 virus infections.

The signing of this acquisition cooperation is undoubtedly an important development opportunity for both Zybio and Shenzhen Thistory Bio-Medical Company.

Supplies of laboratory reagents, testing components and transport media are expected to normalize in the first half of 2023, ending shortages that date back to early in the pandemic, according to the Food and Drug Administration.